Browse > Article
http://dx.doi.org/10.14348/molcells.2022.0058

PARK2 Induces Osteoclastogenesis through Activation of the NF-κB Pathway  

Hong, Seo Jin (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Jung, Suhan (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Jang, Ji Sun (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Mo, Shenzheng (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Kwon, Jun-Oh (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Kim, Min Kyung (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Kim, Hong-Hee (Department of Cell and Developmental Biology, BK21 Program and Dental Research Institute (DRI), School of Dentistry, Seoul National University)
Publication Information
Molecules and Cells / v.45, no.10, 2022 , pp. 749-760 More about this Journal
Abstract
Osteoclast generation from monocyte/macrophage lineage precursor cells needs to be tightly regulated to maintain bone homeostasis and is frequently over-activated in inflammatory conditions. PARK2, a protein associated with Parkinson's disease, plays an important role in mitophagy via its ubiquitin ligase function. In this study, we investigated whether PARK2 is involved in osteoclastogenesis. PARK2 expression was found to be increased during the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation. PARK2 gene silencing with siRNA significantly reduced osteoclastogenesis induced by RANKL, LPS (lipopolysaccharide), TNFα (tumor necrosis factor α), and IL-1β (interleukin-1β). On the other hand, overexpression of PARK2 promoted osteoclastogenesis. This regulation of osteoclastogenesis by PARK2 was mediated by IKK (inhibitory κB kinase) and NF-κB activation while MAPK (mitogen-activated protein kinases) activation was not involved. Additionally, administration of PARK2 siRNA significantly reduced osteoclastogenesis and bone loss in an in vivo model of inflammatory bone erosion. Taken together, this study establishes a novel role for PARK2 as a positive regulator in osteoclast differentiation and inflammatory bone destruction.
Keywords
lipopolysaccharide-induced osteolysis; NF-${\kappa}B$ signaling pathway; osteoclast; PARK2;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Lubbe, S.J., Bustos, B.I., Hu, J., Krainc, D., Joseph, T., Hehir, J., Tan, M., Zhang, W., Escott-Price, V., Williams, N.M., et al. (2021). Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk. Hum. Mol. Genet. 30, 78-86.   DOI
2 Luo, G., Li, F., Li, X., Wang, Z.G., and Zhang, B. (2018). TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway. Mol. Med. Rep. 17, 6605-6611.
3 Madeo, F., Eisenberg, T., Pietrocola, F., and Kroemer, G. (2018). Spermidine in health and disease. Science 359, eaan2788.   DOI
4 Martinez, F.O., Sica, A., Mantovani, A., and Locati, M. (2008). Macrophage activation and polarization. Front. Biosci. 13, 453-461.   DOI
5 Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E.W., Brown, K.D., Leonardi, A., Tran, T., Boyce, B.F., and Siebenlist, U. (1997). Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496.   DOI
6 Gao, F., Chen, D., Si, J.M., Hu, Q.S., Qin, Z.H., Fang, M., and Wang, G.H. (2015). The mitochondrial protein BNIP3L is the substrate of PARK2 and mediates mitophagy in PINK1/PARK2 pathway. Hum. Mol. Genet. 24, 2528-2538.   DOI
7 Goodman, S.B., Gibon, E., Gallo, J., and Takagi, M. (2022). Macrophage polarization and the osteoimmunology of periprosthetic osteolysis. Curr. Osteoporos. Rep. 20, 43-52.   DOI
8 Harper, J.W., Ordureau, A., and Heo, J.M. (2018). Building and decoding ubiquitin chains for mitophagy. Nat. Rev. Mol. Cell Biol. 19, 93-108.   DOI
9 Horne, W.C., Sanjay, A., Bruzzaniti, A., and Baron, R. (2005). The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol. Rev. 208, 106-125.   DOI
10 Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., and Bravo, R. (1997). Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3, 1285-1289.   DOI
11 Kamienieva, I., Duszynski, J., and Szczepanowska, J. (2021). Multitasking guardian of mitochondrial quality: parkin function and Parkinson's disease. Transl. Neurodegener. 10, 5.   DOI
12 Quinn, P.M.J., Moreira, P.I., Ambrosio, A.F., and Alves, C.H. (2020). PINK1/ PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol. Commun. 8, 189.   DOI
13 Muller-Rischart, A.K., Pilsl, A., Beaudette, P., Patra, M., Hadian, K., Funke, M., Peis, R., Deinlein, A., Schweimer, C., Kuhn, P.H., et al. (2013). The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol. Cell 49, 908-921.   DOI
14 Nakamura, I. and Jimi, E. (2006). Regulation of osteoclast differentiation and function by interleukin-1. Vitam. Horm. 74, 357-370. Park, J.H., Lee, N.K., and Lee, S.Y. (2017). Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol. Cells 40, 706-713.
15 Poole, A.C., Thomas, R.E., Yu, S., Vincow, E.S., and Pallanck, L. (2010). The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. Plos One 5, e10054.   DOI
16 Sanjay, A., Houghton, A., Neff, L., DiDomenico, E., Bardelay, C., Antoine, E., Levy, J., Gailit, J., Bowtell, D., Horne, W.C., et al. (2001). Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrinmediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152, 181-195.   DOI
17 Seirafi, M., Kozlov, G., and Gehring, K. (2015). Parkin structure and function. FEBS J. 282, 2076-2088.   DOI
18 Takahashi, N., Ejiri, S., Yanagisawa, S., and Ozawa, H. (2007). Regulation of osteoclast polarization. Odontology 95, 1-9.   DOI
19 Lamothe, B., Webster, W.K., Gopinathan, A., Besse, A., Campos, A.D., and Darnay, B.G. (2007). TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem. Biophys. Res. Commun. 359, 1044-1049.   DOI
20 Kim, J.H. and Kim, N. (2014). Regulation of NFATc1 in osteoclast differentiation. J. Bone Metab. 21, 233-241.   DOI
21 Jin, S.M. and Youle, R.J. (2012). PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 125, 795-799.   DOI
22 Amarasekara, D.S., Yun, H., Kim, S., Lee, N., Kim, H., and Rho, J. (2018). Regulation of osteoclast differentiation by cytokine networks. Immune Netw. 18, e8.   DOI
23 Bhatia, D., Chung, K.P., Nakahira, K., Patino, E., Rice, M.C., Torres, L.K., Muthukumar, T., Choi, A.M., Akchurin, O.M., and Choi, M.E. (2019). Mitophagy-dependent macrophage reprogramming protects against kidney fibrosis. JCI Insight 4, e132826.   DOI
24 Downey, P.A. and Siegel, M.I. (2006). Bone biology and the clinical implications for osteoporosis. Phys. Ther. 86, 77-91.   DOI
25 Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., and Springer, W. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119-131.   DOI
26 Henn, I.H., Bouman, L., Schlehe, J.S., Schlierf, A., Schramm, J.E., Wegener, E., Nakaso, K., Culmsee, C., Berninger, B., Krappmann, D., et al. (2007). Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27, 1868-1878.   DOI
27 Laforge, M., Rodrigues, V., Silvestre, R., Gautier, C., Weil, R., Corti, O., and Estaquier, J. (2016). NF-kappaB pathway controls mitochondrial dynamics. Cell Death Differ. 23, 89-98.   DOI
28 Lin, D.C., Xu, L., Chen, Y., Yan, H., Hazawa, M., Doan, N., Said, J.W., Ding, L.W., Liu, L.Z., Yang, H., et al. (2015). Genomic and functional analysis of the E3 ligase PARK2 in glioma. Cancer Res. 75, 1815-1827.
29 Liu, J., Wang, S., Zhang, P., Said-Al-Naief, N., Michalek, S.M., and Feng, X. (2009). Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J. Biol. Chem. 284, 12512-12523.   DOI
30 Tanaka, S., Amling, M., Neff, L., Peyman, A., Uhlmann, E., Levy, J.B., and Baron, R. (1996). c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383, 528-531.   DOI
31 Wada, T., Nakashima, T., Hiroshi, N., and Penninger, J.M. (2006). RANKLRANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17-25.
32 Walsh, M.C., Kim, G.K., Maurizio, P.L., Molnar, E.E., and Choi, Y. (2008). TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL. Plos One 3, e4064.   DOI
33 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95, 3597-3602.   DOI
34 Zhu, L., Zhao, Q., Yang, T., Ding, W., and Zhao, Y. (2015). Cellular metabolism and macrophage functional polarization. Int. Rev. Immunol. 34, 82-100.   DOI
35 Ziviani, E., Tao, R.N., and Whitworth, A.J. (2010). Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. U. S. A. 107, 5018-5023.   DOI
36 Li, Z., Zhu, X., Xu, R., Wang, Y., Hu, R., and Xu, W. (2019). Deacylcynaropicrin inhibits RANKL-induced osteoclastogenesis by inhibiting NF-kappaB and MAPK and promoting M2 polarization of macrophages. Front. Pharmacol. 10, 599.   DOI
37 Ashrafi, G. and Schwarz, T.L. (2013). The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 20, 31-42.   DOI
38 Besse, A., Lamothe, B., Campos, A.D., Webster, W.K., Maddineni, U., Lin, S.C., Wu, H., and Darnay, B.G. (2007). TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J. Biol. Chem. 282, 3918-3928.   DOI
39 Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature 423, 337-342.   DOI
40 Chen, J. and Chen, Z.J. (2013). Regulation of NF-kappaB by ubiquitination. Curr. Opin. Immunol. 25, 4-12.   DOI
41 Wang, Y., Shan, B., Liang, Y., Wei, H., and Yuan, J. (2018). Parkin regulates NF-kappaB by mediating site-specific ubiquitination of RIPK1. Cell Death Dis. 9, 732.   DOI
42 Yamamoto, T., Hinoi, E., Fujita, H., Iezaki, T., Takahata, Y., Takamori, M., and Yoneda, Y. (2012). The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice. Br. J. Pharmacol. 166, 1084-1096   DOI
43 Zhao, Z., Hou, X., Yin, X., Li, Y., Duan, R., Boyce, B.F., and Yao, Z. (2015). TNF induction of NF-kappaB RelB enhances RANKL-induced osteoclastogenesis by promoting inflammatory macrophage differentiation but also limits it through suppression of NFATc1 expression. Plos One 10, e0135728.   DOI
44 Zhou, X., Li, Y., Wang, W., Wang, S., Hou, J., Zhang, A., Lv, B., Gao, C., Yan, Z., Pang, D., et al. (2020). Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2. Theranostics 10, 9443-9457.   DOI
45 Zou, W. and Bar-Shavit, Z. (2002). Dual modulation of osteoclast differentiation by lipopolysaccharide. J. Bone Miner. Res. 17, 1211-1218.   DOI